Contingency Management for Meth in South Africa Methamphetamine Abuse in South Africa

NCT ID: NCT02907853

Last Updated: 2019-05-10

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 28 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-09-01
• Study Completion Date: 2018-02-15

Brief Summary

This study will link findings from neuroscience with clinical outcomes using contingency management (CM) to identify changes in brain structure and function that emerge during purely behavioral therapy for methamphetamine (MA) use.

Detailed Description

This study will correlate MA-abstinence outcomes from an 8-week program of voucher-based incentives using an escalating schedule for 30 treatment-seeking, MA-dependent individuals with scores on tasks of working memory and assessments of neuropsychological and demographic status. At the beginning and end of the CM program, participants will participate in MRI scans while performing a working memory task and will complete a battery of select neurocognitive and psychological assays to address two specific aims: (1) to determine whether changes in neural function within frontostriatal circuitry from baseline to end of the 8-week CM program are associated with parallel changes in measures of cognitive control and impulsivity and with MA abstinence outcomes and (2) to determine whether structural changes in frontostriatal circuitry over the 8-week CM intervention correspond with neurocognitive, psychological and MA abstinence measures.

Conditions

Methamphetamine Abuse

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Contingency Management

In exchange for consecutive urine samples documenting methamphetamine abstinence, participants receive increasingly valuable reinforcers.

Group Type: EXPERIMENTAL

Contingency Management

Intervention Type: BEHAVIORAL

as described above

Interventions

Contingency Management

as described above

Intervention Type: BEHAVIORAL

Eligibility Criteria

Inclusion Criteria

• provide voluntary informed consent
• meet DSM-5 criteria for MA or amphetamine use disorder
• provide at least one urine sample positive for MA/amphetamine metabolites during screening (i.e. prior to the commencement of the study).
• aged 18-45
• right-handed
• English-speaking

Exclusion Criteria

• currently receiving treatment for stimulant addiction or needing more intensive treatment than outpatient care
• meet DSM-5 criteria for substance use disorder other than nicotine
• unable to attend 4+ visits during the 2-week screening period or to complete measures
• Physical or mental illness that would require intervention that would alter imaging or that would interfere with safe study participation
• pregnant, claustrophobic, or have metal prostheses, cardiac pacemakers, or metal clips that are incompatible with the scanner
• HIV positive status
• unable to comprehend written or spoken English
• currently taking psychiatric medication

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University of Cape Town

OTHER

Sponsor Role: collaborator

University of California, Los Angeles

OTHER

Sponsor Role: lead

Responsible Party

Steve Shoptaw

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Department of Psychiatry at Groote Schuur Hospital

Cape Town, , South Africa

Countries

South Africa

Other Identifiers

R21CMinSA

Identifier Type: -

Identifier Source: org_study_id

NCT02948868

Identifier Type: -

Identifier Source: nct_alias